Uploaded July 2025 | Updated September 2026, 2 weeks ago
Dr. Mark Scialdone is a recognized expert in the field of organic chemistry, specializing in natural product chemistry, including plant oil extraction, analysis, and chemical modification. He is an inventor of 37 issued US patents and has authored 17 peer-reviewed publications, during more than two decades of fundamental and product development research. He has given numerous invited lectures at more than 40 different academic institutions and international symposia.
At CannMed 25, Mark participated in the Hemp-Derived Cannabinoids panel, which explored the rapid rise of products containing chemically transformed cannabinoids to exploit the 2018 Farm Bill loophole. He also presented a poster that explained the process for chemically converting cannabinoids in more detail.
During our conversation we discussed:
* Why producers and manufacturers would want to convert one cannabinoid into another
* Common methods for cannabinoid conversion
* Safety risks associated with chemical cannabinoid conversion
* The legality of these compounds
* How these compouns and these products are affecting the legal cannabis market
* The therapeutic potential of novel, chemically-converted cannabinoids
* and more
Thanks to This Episode’s Sponsor: Cannabis & Tech Today
Cannabis & Tech Today is the premier publication for the business, science, and innovations shaping the cannabis industry. From exclusive interviews with industry leaders to deep dives on the latest tech, they cover it all.
Go to cannatechtoday.com to subscribe to their digital and print editions and gain access to exclusive interviews, brand-new technology, and thought-provoking articles from every corner of the cannabis community.
Additional Resources
* Pre-Register for CannMed 26 for just $100 (cvent.me/ryXrgZ)
* CannMed Video Archive (cannmedevents.com/cannmed-video-archives/)
* Connect with Mark on LinkedIn (linkedin.com/in/mark-scialdone-0247625b/)
* The Dark Side of Cannabidiol (CBD): The Unanticipated Social and Clinical Implications of Synthetic Δ8-THC (pubmed.ncbi.nlm.nih.gov/36264171/)
* Hash Church on YouTube (youtube.com/playlist?list=PL668WdsJxoe3m1XJPFCBQ2h4JUy8ulCLx)
* CANN Delta-8-THC Panel Discussion (youtu.be/rdbQXLfKREg?si=Rrrk7gKpC4fH2ELJ)
* GC Separation for Identification of iso-THC Contaminants and Accurate Quantification of Δ8 -THC and Δ9-THC in Cannabis Samples (caymanchem.com/literature/GC-Identification-of-iso-THC-Contaminants?srsltid=AfmBOoqiSA7-_N7g0lObACmVbGrCjyY3yrbCscyNkuDBws-o-_4-fId5)
Dr. Mark Scialdone is a recognized expert in the field of organic chemistry, specializing in natural product chemistry, including plant oil extraction, analysis, and chemical modification. He is an inventor of 37 issued US patents and has authored 17 peer-reviewed publications, during more than two decades of fundamental and product development research. He has given numerous invited lectures at more than 40 different academic institutions and international symposia.
At CannMed 25, Mark participated in the Hemp-Derived Cannabinoids panel, which explored the rapid rise of products containing chemically transformed cannabinoids to exploit the 2018 Farm Bill loophole. He also presented a poster that explained the process for chemically converting cannabinoids in more detail.
During our conversation we discussed:
* Why producers and manufacturers would want to convert one cannabinoid into another
* Common methods for cannabinoid conversion
* Safety risks associated with chemical cannabinoid conversion
* The legality of these compounds
* How these compouns and these products are affecting the legal cannabis market
* The therapeutic potential of novel, chemically-converted cannabinoids
* and more
Thanks to This Episode’s Sponsor: Cannabis & Tech Today
Cannabis & Tech Today is the premier publication for the business, science, and innovations shaping the cannabis industry. From exclusive interviews with industry leaders to deep dives on the latest tech, they cover it all.
Go to cannatechtoday.com to subscribe to their digital and print editions and gain access to exclusive interviews, brand-new technology, and thought-provoking articles from every corner of the cannabis community.
Additional Resources
* Pre-Register for CannMed 26 for just $100 (cvent.me/ryXrgZ)
* CannMed Video Archive (cannmedevents.com/cannmed-video-archives/)
* Connect with Mark on LinkedIn (linkedin.com/in/mark-scialdone-0247625b/)
* The Dark Side of Cannabidiol (CBD): The Unanticipated Social and Clinical Implications of Synthetic Δ8-THC (pubmed.ncbi.nlm.nih.gov/36264171/)
* Hash Church on YouTube (youtube.com/playlist?list=PL668WdsJxoe3m1XJPFCBQ2h4JUy8ulCLx)
* CANN Delta-8-THC Panel Discussion (youtu.be/rdbQXLfKREg?si=Rrrk7gKpC4fH2ELJ)
* GC Separation for Identification of iso-THC Contaminants and Accurate Quantification of Δ8 -THC and Δ9-THC in Cannabis Samples (caymanchem.com/literature/GC-Identification-of-iso-THC-Contaminants?srsltid=AfmBOoqiSA7-_N7g0lObACmVbGrCjyY3yrbCscyNkuDBws-o-_4-fId5)
![How Would Rescheduling THC to Schedule III Impact Clinical Trials?
Dr. Emily Lindley is Assistant Professor of Orthopedics and Director of the Colorado Cannabis Research Consortium. Her team’s research aims to identify non-opioid alternatives for the treatment of chronic musculoskeletal pain. One such alternative that has gained increased recognition in recent years is medical cannabis, and her lab is currently studying the health effects of cannabis and cannabinoids for chronic musculoskeletal pain.
Dr. Rachael Rzasa Lynn is a board certified in pain medicine physician and is an Associate Professor in the Department of Anesthesiology at the University of Colorado, where she is the Associate Program Director for the Pain Medicine Fellowship. Her research includes investigations in opioid pharmacology and the use of cannabis for chronic pain.
Rachel and Emily co-authored a poster presented at the most recent ICRS conference titled, Recruitment Challenges in Clinical Studies of Cannabis
During our conversation, we discussed:
* How recruitment for cannabis clinical trials differs from traditional clinical trials
* Why prior experience with cannabis is considered a negative for patient recruitment
* How legal concerns and stigma can deter cannabis-naive patients from enrolling
* Why the participant drop out rate is higher in cannabis trials
* How rescheduling may affect patient recruitment for future trials
Thanks to This Episodes Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians’ Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice.
Learn more at cannabisclinicians.org and use code CP15 to receive 15% Off Your Registration
Additional Resources
* Recruitment Challenges in Clinical Studies of Cannabis [Poster] - https://cannmedevents.com/wp-content/uploads/2025/08/P2-21-Recruitment-Challenges-Poster-ICRS-2025.pdf
* Lindley Lab at the University of Colorado - https://medschool.cuanschutz.edu/orthopedics/research/labs/lindley-lab/our-research How Would Rescheduling THC to Schedule III Impact Clinical Trials?](https://i.ytimg.com/vi/UgSaRtD9l7w/mqdefault.jpg)









